Oruka Therapeutics
ORKA
16 hedge funds and large institutions have $1.24M invested in Oruka Therapeutics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 7 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
0.13% less ownership
Funds ownership: 0.21% → 0.08% (-0.13%)
11% less funds holding
Funds holding: 18 → 16 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
83% less capital invested
Capital invested by funds: $7.39M → $1.24M (-$6.15M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$502K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$431K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$125K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$60.1K |
| 5 |
VF
Virtu Financial
New York
|
+$55.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$1.97M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$1.67M |
| 3 |
VMI
VHCP Management II
New York
|
-$1.46M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$138K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$79.7K |
ORKA Hedge Fund Activity: Q1 2018 in Review
16 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2018, worth a combined $1.24M — down 83% from $7.39M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ORKA and 5 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $502K. The largest seller was NEA Management Company, exiting entirely with an estimated $1.97M sold.
- 16 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2018, down from 18 in Q4 2017.
- Funds reported $1.24M of Oruka Therapeutics stock for Q1 2018, down 83% quarter-over-quarter.
- 5 funds opened new Oruka Therapeutics positions in Q1 2018 and 7 closed out, a net change of -2 holders.
- The largest Oruka Therapeutics buyer in Q1 2018 was Renaissance Technologies, an estimated $502K added.
- The largest Oruka Therapeutics seller in Q1 2018 was NEA Management Company, an estimated $1.97M sold.
Based on aggregated 13F filings for Q1 2018.